Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H50O7 |
Molecular Weight | 570.7566 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]3(C)C2=CC(=O)[C@]4([H])[C@@]5(C)CC[C@H](OC(=O)CCC(O)=O)C(C)(C)[C@]5([H])CC[C@@]34C)C(O)=O
InChI
InChIKey=OBZHEBDUNPOCJG-WBXJDKIVSA-N
InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22473546Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/780088 |
https://www.ncbi.nlm.nih.gov/pubmed/4564085 | https://www.ncbi.nlm.nih.gov/pubmed/3418512 | https://www.ncbi.nlm.nih.gov/pubmed/9029719 | http://onlinelibrary.wiley.com/doi/10.1111/j.2042-7158.1960.tb12629.x/pdf | http://www.hpra.ie/img/uploaded/swedocuments/2122523.PA0074_011_001.71e04f1c-dfd8-4e60-916a-6ba998cf37c0.000001Product%20Leaflet%20Approved.131003.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22473546
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/780088 |
https://www.ncbi.nlm.nih.gov/pubmed/4564085 | https://www.ncbi.nlm.nih.gov/pubmed/3418512 | https://www.ncbi.nlm.nih.gov/pubmed/9029719 | http://onlinelibrary.wiley.com/doi/10.1111/j.2042-7158.1960.tb12629.x/pdf | http://www.hpra.ie/img/uploaded/swedocuments/2122523.PA0074_011_001.71e04f1c-dfd8-4e60-916a-6ba998cf37c0.000001Product%20Leaflet%20Approved.131003.pdf
Carbenoxolone is a glycyrrhetinic acid derivative with a steroid-like structure, similar to substances found in the flavor-ful root of the licorice plant. It influences endogenous glucocorticoids by potently inhibiting 11β-hydroxysteroid dehydrogenase. Electrolyte imbalance is a serious side effect of carbenoxolone when used systemically. Carbenoxolone is best known in cellular physiology as a modestly potent, reasonably effective, water-soluble blocker of gap junctions. It exerts anti-inflammatory activity. Carbenoxolone has used orally in the clinical treatment of peptic ulcers, now it is used topically for the treatment of lip sores and mouth ulcers.
Originator
Sources: http://www.sciencedirect.com/science/article/pii/S0140673659906117?showall%3Dtrue%26via%3Dihub
Curator's Comment: 1959
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3542430 |
|||
Target ID: GO:0016264 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3418512 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARBOSAN Approved UseCarbosan Gel is used for the treatment of lip sores and mouth ulcers. |
PubMed
Title | Date | PubMed |
---|---|---|
Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line. | 2005 Apr |
|
Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1. | 2006 Jun 1 |
|
Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. | 2009 Feb |
|
Gastroprotective mechanisms of Citrus lemon (Rutaceae) essential oil and its majority compounds limonene and β-pinene: involvement of heat-shock protein-70, vasoactive intestinal peptide, glutathione, sulfhydryl compounds, nitric oxide and prostaglandin E₂. | 2011 Jan 15 |
|
Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes. | 2013 Sep |
|
Gastroprotective effects of goniothalamin against ethanol and indomethacin-induced gastric lesions in rats: Role of prostaglandins, nitric oxide and sulfhydryl compounds. | 2014 Dec 5 |
Patents
Sample Use Guides
Cabosan 2% w/w Gel (Carbenoxolone Sodium). Carbosan Gel is used for the treatment of lip sores and mouth ulcers.
Route of Administration:
Transdermal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16552723
100 uM carbenoxolone induces Connexin-43 expression in bovine aortic endothelial cells
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA02BX71
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
||
|
NCI_THESAURUS |
C54678
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
||
|
FDA ORPHAN DRUG |
429414
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
||
|
WHO-ATC |
A02BX71
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
||
|
WHO-VATC |
QA02BX01
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
||
|
WHO-ATC |
A02BX51
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
||
|
WHO-ATC |
A02BX01
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
493
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
2017
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | RxNorm | ||
|
MM6384NG73
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
1789
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
SUB06123MIG
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
227-174-2
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
DB02329
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
CARBENOXOLONE
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
m3064
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
636403
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL499915
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
C63669
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
100000081319
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
DTXSID4022733
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
5697-56-3
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY | |||
|
D002229
Created by
admin on Fri Dec 15 15:53:07 GMT 2023 , Edited by admin on Fri Dec 15 15:53:07 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)